These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 17526545

  • 1. Maintaining control over haemoglobin levels: optimizing the management of anaemia in chronic kidney disease.
    Bárány P, Müller HJ.
    Nephrol Dial Transplant; 2007 Jun; 22 Suppl 4():iv10-iv18. PubMed ID: 17526545
    [Abstract] [Full Text] [Related]

  • 2. [Regarding the optimal hemoglobin target range in renal anemia].
    Maurin N.
    Med Klin (Munich); 2008 Sep 15; 103(9):633-7. PubMed ID: 18813886
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
    Sulowicz W, Locatelli F, Ryckelynck JP, Balla J, Csiky B, Harris K, Ehrhard P, Beyer U, PROTOS Study Investigators.
    Clin J Am Soc Nephrol; 2007 Jul 15; 2(4):637-46. PubMed ID: 17699476
    [Abstract] [Full Text] [Related]

  • 6. Optimal treatment of renal anaemia (OPTA): improving the efficacy and efficiency of renal anaemia therapy in haemodialysis patients receiving intravenous epoetin.
    Hörl WH, Vanrenterghem Y, Canaud B, Mann J, Teatini U, Wanner C, Wikström B.
    Nephrol Dial Transplant; 2005 May 15; 20 Suppl 3():iii25-32. PubMed ID: 15824127
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Anaemia management in non-dialysis chronic kidney disease: flexibility of target to target stability?
    De Nicola L, Minutolo R, Conte G.
    Nephron Clin Pract; 2010 May 15; 114(4):c236-41. PubMed ID: 20090364
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
    Provenzano R, Besarab A, Macdougall IC, Ellison DH, Maxwell AP, Sulowicz W, Klinger M, Rutkowski B, Correa-Rotter R, Dougherty FC, BA 16528 Study Investigators.
    Clin Nephrol; 2007 May 15; 67(5):306-17. PubMed ID: 17542340
    [Abstract] [Full Text] [Related]

  • 16. Changes in erythropoiesis-stimulating agent (ESA) dosing and haemoglobin levels in US non-dialysis chronic kidney disease patients between 2005 and 2009.
    Regidor D, McClellan WM, Kewalramani R, Sharma A, Bradbury BD.
    Nephrol Dial Transplant; 2011 May 15; 26(5):1583-91. PubMed ID: 20861195
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Update on anemia management in nephrology, including current guidelines on the use of erythropoiesis-stimulating agents and implications of the introduction of "biosimilars".
    Locatelli F, Becker H.
    Oncologist; 2009 May 15; 14 Suppl 1():16-21. PubMed ID: 19762513
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.